Migraine in ChildrenNCT06966037
Uric Acid Levels and Migraine in Children
An observational study of Migraine in Children, run by Aysen Orman at 1 site in Turkey (Türkiye).
Trial summary
Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Read more about this study
- Who is it for?
- Ages 6 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Migraine in Children
- How many people
- 2 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Aug 2019to 1 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Patients diagnosed with migraine were included as the study group, while the control group consisted of patients who presented to the pediatric neurology clinic during the same period for neuromotor development follow-up examinations.
Who may be able to join
- Patients diagnosed with migraine
- Healthy children Exclusion Criteria Neuromotor developmental delay Multiple congenital anomalies Non-migraine headache Epilepsy
Who cannot join
- Cerebral palsy Non-migraine headache Epilepsy Multiple congenital anomalies Congenital metabolic diseases Control group
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Uric Acid Levels in Pediatric Patients With Migraine
Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Additionally, this study seeks to explore the potential relationship between migraine attack frequency and gender differences in pediatric patients
Read the detailed description
Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Additionally, this study seeks to explore the potential relationship between migraine attack frequency and gender differences in pediatric patients Patients diagnosed with migraine were included as the study group, while the control group consisted of patients who presented to the pediatric neurology clinic during the same period for neuromotor development follow-up examinations.
Migraine patients are influenced by multiple factors, including dietary habits, levels of physical activity, and various psychosocial determinants.
- Conditions
- Migraine in Children
- Keywords
- migraine, children, uric acid levels
- Medical subject headings
- Migraine Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Comparison of Laboratory Parameters Between Groups | The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of Uric Acid Levels in Pediatric Patients with Migraine
Migraine represents a significant neurological condition affecting individuals across all age groups, with a reported prevalence of 7.7% among children and adolescents. According to the widely accepted neurogenic inflammation hypothesis, sterile inflammation occurs in the dura mater surrounding the brain as a result of neuropeptide release from perivascular trigeminal nerve endings, leading to sensitization of sensory neurons .Uric acid is known to function as a potent endogenous antioxidant and free radical scavenger within the human body. It has been suggested that uric acid exerts dual effects on the central nervous system, demonstrating both neuroprotective and neurotoxic properties depending on its concentration. Although uric acid may enhance antioxidant and anti-inflammatory responses at physiological concentrations, it has been suggested that excessively elevated serum uric acid levels may contribute to increased oxidative stress and subsequent neuronal damage. The primary ou
Measured: 01.08.2019 and 01.03.2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2025
- Study start1 Aug 2019
- Primary completion1 Jan 2025
- Study completion1 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Migraine in ChildrenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 2 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aysen Orman
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Aysen Orman, Mersin University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06966037
- Sponsor's protocol ID
- Balikesir University
- Status last verified
- May 2025
- First submitted
- 24 Apr 2025
- Last updated
- 11 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Uric Acid Levels in Pediatric Patients With Migraine
- ClinicalTrials.gov ID
- NCT06966037
- Acronym / sponsor ID
- Balikesir University
- Conditions
- Migraine in Children
- Keywords
- migraine, children, uric acid levels
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2 participants (actual)
- Lead sponsor
- Aysen OrmanUniversity, hospital or other
- Study start
- 1 Aug 2019 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 1 Apr 2025 (actual)
- First posted
- 11 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Additionally, this study seeks to explore the potential relationship between migraine attack frequency and gender differences in pediatric patients
Detailed description
Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Additionally, this study seeks to explore the potential relationship between migraine attack frequency and gender differences in pediatric patients Patients diagnosed with migraine were included as the study group, while the control group consisted of patients who presented to the pediatric neurology clinic during the same period for neuromotor development follow-up examinations.
Migraine patients are influenced by multiple factors, including dietary habits, levels of physical activity, and various psychosocial determinants.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Comparison of Laboratory Parameters Between Groups | – | –The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group |
Who may qualify
- Ages
- 6 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Patients diagnosed with migraine were included as the study group, while the control group consisted of patients who presented to the pediatric neurology clinic during the same period for neuromotor development follow-up examinations.
Key inclusion criteria (2 listed)
- Patients diagnosed with migraine
- Healthy children Exclusion Criteria Neuromotor developmental delay Multiple congenital anomalies Non-migraine headache Epilepsy
Key exclusion criteria (1 listed)
- Cerebral palsy Non-migraine headache Epilepsy Multiple congenital anomalies Congenital metabolic diseases Control group
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of Uric Acid Levels in Pediatric Patients with Migraine
Time frame: 01.08.2019 and 01.03.2024
Migraine represents a significant neurological condition affecting individuals across all age groups, with a reported prevalence of 7.7% among children and adolescents. According to the widely accepted neurogenic inflammation hypothesis, sterile inflammation occurs in the dura mater surrounding the brain as a result of neuropeptide release from perivascular trigeminal nerve endings, leading to sensitization of sensory neurons .Uric acid is known to function as a potent endogenous antioxidant and free radical scavenger within the human body. It has been suggested that uric acid exerts dual effects on the central nervous system, demonstrating both neuroprotective and neurotoxic properties depending on its concentration. Although uric acid may enhance antioxidant and anti-inflammatory responses at physiological concentrations, it has been suggested that excessively elevated serum uric acid levels may contribute to increased oxidative stress and subsequent neuronal damage. The primary ou
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2025.
- Individual participant dataSharing planned: Yes
Related trials for Migraine in Children
RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric Migraine
RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of Migraine
RecruitingPhase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Chronic Migraine in Children
RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Migraine
RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Migraine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Migraine in Children, run by Aysen Orman at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of Uric Acid Levels in Pediatric Patients with Migraine (time frame: 01.08.2019 and 01.03.2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2025.